Protia Inc. (KOSDAQ:303360)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,805.00
-30.00 (-0.62%)
At close: Mar 20, 2026
Market Cap61.88B +46.7%
Revenue (ttm)13.52B +36.8%
Net Income3.80B +166.9%
EPS294.87 +169.2%
Shares Out12.88M
PE Ratio16.30
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume45,064
Average Volume38,839
Open4,835.00
Previous Close4,835.00
Day's Range4,710.00 - 4,895.00
52-Week Range2,885.00 - 6,890.00
Beta0.06
RSI41.21
Earnings Daten/a

About Protia

Protia Inc. manufactures and sells in vitro diagnostic medical devices in South Korea. It offers allergy, animal diagnosis, autoimmune, antibiotic susceptibility, POCT, cancer, and related instrument products, as well as protein analysis, LC-MS/MS, characterization analysis, and custom protein services. The company was formerly known as ProteomeTech Inc. and changed its name to Protia Inc. in November 2023. Protia Inc. was founded in 2000 and is headquartered in Seoul, South Korea. [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 303360
Full Company Profile

Financial Performance

In 2024, Protia's revenue was 10.51 billion, an increase of 27.79% compared to the previous year's 8.23 billion. Earnings were 2.44 billion, an increase of 427.52%.

Financial Statements